← Back to Search

Anti-angiogenic Drug Combination

TL-118 with standard of care Gemcitabine for Pancreatic Cancer

Phase 2
Waitlist Available
Research Sponsored by Tiltan Pharma Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up measured at week 16 and 52
Awards & highlights

Study Summary

TL-118 is an anti-angiogenic drug combination designed for the treatment of cancer. The investigational product Tl-118 comprises of four well-known active components. The therapy is administrated at a unique dosing regimen that was found to be effective and advantageous in terms of safety. The product is formulated as an oral suspension, conveniently administrated by the patients at home and not requiring medical staff assistance. This Phase II clinical trial aims to evaluate the efficacy, safety and tolerability of TL-118 in Gemcitabine treated Pancreatic Cancer patients

Eligible Conditions
  • Pancreatic Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~measured at week 16 and 52
This trial's timeline: 3 weeks for screening, Varies for treatment, and measured at week 16 and 52 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Disease Control Rate as defined by Percentage of patients experiencing a Complete Response or a Partial Response or a Stable Disease according to RECIST measured at 16 weeks after treatment initiation
Secondary outcome measures
Overall Survival
Progression free survival
Quality of life
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: TL-118 with standard of care GemcitabineExperimental Treatment1 Intervention
Group II: Gemcitabine with out TL-118Active Control1 Intervention

Find a Location

Who is running the clinical trial?

Tiltan Pharma Ltd.Lead Sponsor
2 Previous Clinical Trials
110 Total Patients Enrolled
TechnostatUNKNOWN
1 Previous Clinical Trials
75 Total Patients Enrolled
NovatrialsUNKNOWN

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Clinical Trial of Anti-Angiogenic Drug Combination Tl-118 for Pancreatic Cancer Patients Who Are Starting Gemcitabine Treatment
2012. "A Clinical Trial of Anti-Angiogenic Drug Combination Tl-118 for Pancreatic Cancer Patients Who Are Starting Gemcitabine Treatment". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01509911.
~7 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top